Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
出版年份 2021 全文链接
标题
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 9, Pages 4467
出版商
MDPI AG
发表日期
2021-04-25
DOI
10.3390/ijms22094467
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
- (2021) Stephen K. Brannan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Potential Role of Lumateperone—Something Borrowed? Something New?
- (2020) Joshua T. Kantrowitz JAMA Psychiatry
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
- (2020) Christoph U. Correll et al. JAMA Psychiatry
- Potential Roles of Redox Dysregulation in the Development of Schizophrenia
- (2020) Diana O. Perkins et al. BIOLOGICAL PSYCHIATRY
- Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine
- (2020) Michelle Kokkinou et al. MOLECULAR PSYCHIATRY
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus
- (2020) Susan F. Sonnenschein et al. NEUROPSYCHOPHARMACOLOGY
- Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
- (2020) Susan F. Sonnenschein et al. Frontiers in Psychiatry
- Prepubertal environmental enrichment prevents dopamine dysregulation and hippocampal hyperactivity in MAM schizophrenia model rats.
- (2020) Xiyu Zhu et al. BIOLOGICAL PSYCHIATRY
- Stress impacts corticoamygdalar connectivity in an age-dependent manner
- (2020) Daniela L. Uliana et al. NEUROPSYCHOPHARMACOLOGY
- Stress during critical periods of development and risk for schizophrenia
- (2019) Felipe V. Gomes et al. SCHIZOPHRENIA RESEARCH
- T108. AUT00206, A NOVEL KV3 CHANNEL MODULATOR, REDUCES KETAMINE-INDUCED BOLD SIGNALLING IN HEALTHY MALE VOLUNTEERS: A RANDOMISED PLACEBO-CONTROLLED CROSSOVER TRIAL
- (2019) Bill Deakin et al. SCHIZOPHRENIA BULLETIN
- SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION
- (2019) Nina Dedic et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
- (2019) Maximilian Huhn et al. LANCET
- Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner
- (2019) J. J. Donegan et al. Nature Communications
- The pathophysiological impact of stress on the dopamine system is dependent on the state of the critical period of vulnerability
- (2019) Felipe V. Gomes et al. MOLECULAR PSYCHIATRY
- Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies
- (2019) Stephen J. Kaar et al. JOURNAL OF NEURAL TRANSMISSION
- The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [11C]-(+)-PHNO PET study
- (2019) Tarik Dahoun et al. Translational Psychiatry
- Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate
- (2018) Stephen M. Stahl CNS SPECTRUMS
- α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia
- (2018) Gilda A Neves et al. NEUROPSYCHOPHARMACOLOGY
- The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention
- (2018) Anthony A Grace et al. SCHIZOPHRENIA BULLETIN
- State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia
- (2018) Susan F. Sonnenschein et al. NEUROPSYCHOPHARMACOLOGY
- Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
- (2018) Kimberly E. Vanover et al. NEUROPSYCHOPHARMACOLOGY
- K v 3.1/K v 3.2 channel positive modulators enable faster activating kinetics and increase firing frequency in fast-spiking GABAergic interneurons
- (2017) Kim Boddum et al. NEUROPHARMACOLOGY
- Kv3 Channels: Enablers of Rapid Firing, Neurotransmitter Release, and Neuronal Endurance
- (2017) Leonard K. Kaczmarek et al. PHYSIOLOGICAL REVIEWS
- N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
- (2017) Philippe Conus et al. SCHIZOPHRENIA BULLETIN
- M102. Prefrontal Cortex Dysfunction Increases Susceptibility to Schizophrenia-Like Changes Induced by Adolescent Stress Exposure
- (2017) Felipe Gomes et al. SCHIZOPHRENIA BULLETIN
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
- (2017) Marco Solmi et al. Therapeutics and Clinical Risk Management
- Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2017) Chieh-Hsin Lin et al. BIOLOGICAL PSYCHIATRY
- Treatment in early psychosis with N-acetyl-cysteine for 6 months improves low-level auditory processing: Pilot study
- (2017) Chrysa Retsa et al. SCHIZOPHRENIA RESEARCH
- Loss of Parvalbumin in the Hippocampus of MAM Schizophrenia Model Rats Is Attenuated by Peripubertal Diazepam
- (2016) Yijuan Du et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Modelling the cognitive and neuropathological features of schizophrenia with phencyclidineAbdul-MonimZNeillJCReynoldsGP (2007) Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol21:198–205.
- (2016) Gavin P Reynolds et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression
- (2016) Anthony A. Grace NATURE REVIEWS NEUROSCIENCE
- Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release
- (2016) Daniel J. Foster et al. NEURON
- Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration
- (2016) Yijuan Du et al. NEUROPSYCHOPHARMACOLOGY
- Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model
- (2016) Felipe V. Gomes et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses
- (2016) J. Lally et al. PSYCHOLOGICAL MEDICINE
- Adversity in childhood linked to elevated striatal dopamine function in adulthood
- (2016) Alice Egerton et al. SCHIZOPHRENIA RESEARCH
- Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population
- (2016) Hannah J. Jones et al. JAMA Psychiatry
- Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia
- (2015) Bruce J. Kinon et al. BIOLOGICAL PSYCHIATRY
- Alterations in Cortical Network Oscillations and Parvalbumin Neurons in Schizophrenia
- (2015) Guillermo Gonzalez-Burgos et al. BIOLOGICAL PSYCHIATRY
- The GABA System in Schizophrenia: Cells, Molecules and Microcircuitry
- (2015) Francine M. Benes SCHIZOPHRENIA RESEARCH
- GABAergic mechanisms of hippocampal hyperactivity in schizophrenia
- (2015) Stephan Heckers et al. SCHIZOPHRENIA RESEARCH
- Schizophrenia
- (2015) René S. Kahn et al. Nature Reviews Disease Primers
- A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
- (2014) AnnCatherine M Downing et al. BMC Psychiatry
- The Role of α5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia
- (2014) Kathryn Gill et al. CURRENT PHARMACEUTICAL DESIGN
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model
- (2014) Kathryn M. Gill et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Juvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia
- (2014) Jan-Harry Cabungcal et al. NEURON
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- Prior Antipsychotic Drug Treatment Prevents Response to Novel Antipsychotic Agent in the Methylazoxymethanol Acetate Model of Schizophrenia
- (2014) K. M. Gill et al. SCHIZOPHRENIA BULLETIN
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
- (2013) David H Adams et al. BMC Psychiatry
- Differential regulation of parvalbumin and calretinin interneurons in the prefrontal cortex during adolescence
- (2013) Adriana Caballero et al. Brain Structure & Function
- Region-specific upregulation of parvalbumin-, but not calretinin-positive cells in the ventral hippocampus during adolescence
- (2013) Adriana Caballero et al. HIPPOCAMPUS
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
- (2013) E M P Poels et al. MOLECULAR PSYCHIATRY
- NMDA receptor-dependent function and plasticity in inhibitory circuits
- (2013) Alexandre W. Moreau et al. NEUROPHARMACOLOGY
- Peripubertal Diazepam Administration Prevents the Emergence of Dopamine System Hyperresponsivity in the MAM Developmental Disruption Model of Schizophrenia
- (2013) Yijuan Du et al. NEUROPSYCHOPHARMACOLOGY
- Abnormal Stress Responsivity in a Rodent Developmental Disruption Model of Schizophrenia
- (2013) Eric C Zimmerman et al. NEUROPSYCHOPHARMACOLOGY
- Perineuronal nets protect fast-spiking interneurons against oxidative stress
- (2013) J.-H. Cabungcal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cigarette Smoking Among Persons With Schizophrenia or Bipolar Disorder in Routine Clinical Settings, 1999–2011
- (2013) Faith Dickerson et al. PSYCHIATRIC SERVICES
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- Stress in Puberty Unmasks Latent Neuropathological Consequences of Prenatal Immune Activation in Mice
- (2013) S. Giovanoli et al. SCIENCE
- Add-on Treatment of Benzoate for Schizophrenia
- (2013) Hsien-Yuan Lane et al. JAMA Psychiatry
- Mechanisms of Gamma Oscillations
- (2012) György Buzsáki et al. Annual Review of Neuroscience
- Predicting Psychosis
- (2012) Paolo Fusar-Poli ARCHIVES OF GENERAL PSYCHIATRY
- The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment
- (2012) Oliver D. Howes et al. ARCHIVES OF GENERAL PSYCHIATRY
- Glutamatergic transmission in schizophrenia
- (2012) Joshua Kantrowitz et al. CURRENT OPINION IN PSYCHIATRY
- A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia
- (2012) Mark Weiser et al. JOURNAL OF CLINICAL PSYCHIATRY
- NMDA Receptor Hypofunction, Parvalbumin-Positive Neurons, and Cortical Gamma Oscillations in Schizophrenia
- (2012) G. Gonzalez-Burgos et al. SCHIZOPHRENIA BULLETIN
- Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 Receptor
- (2011) S. Espinoza et al. MOLECULAR PHARMACOLOGY
- GABAergic interneuron origin of schizophrenia pathophysiology
- (2011) Kazu Nakazawa et al. NEUROPHARMACOLOGY
- Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
- (2011) Daniela Alberati et al. NEUROPHARMACOLOGY
- A Novel α5GABAAR-Positive Allosteric Modulator Reverses Hyperactivation of the Dopamine System in the MAM Model of Schizophrenia
- (2011) Kathryn M Gill et al. NEUROPSYCHOPHARMACOLOGY
- Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
- (2011) Carrie K Jones et al. NEUROPSYCHOPHARMACOLOGY
- Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
- (2011) David A. Lewis et al. TRENDS IN NEUROSCIENCES
- Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
- (2010) Richard Mailman et al. CURRENT PHARMACEUTICAL DESIGN
- Redox Dysregulation Affects the Ventral But Not Dorsal Hippocampus: Impairment of Parvalbumin Neurons, Gamma Oscillations, and Related Behaviors
- (2010) P. Steullet et al. JOURNAL OF NEUROSCIENCE
- A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors
- (2010) J. Jeon et al. JOURNAL OF NEUROSCIENCE
- The environment and schizophrenia
- (2010) Jim van Os et al. NATURE
- Metabotropic glutamate receptors: From the workbench to the bedside
- (2010) F. Nicoletti et al. NEUROPHARMACOLOGY
- Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
- (2010) Tyler A Lesh et al. NEUROPSYCHOPHARMACOLOGY
- Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion
- (2010) Alan L. Pehrson et al. PSYCHOPHARMACOLOGY
- High dose D-serine in the treatment of schizophrenia
- (2010) Joshua T. Kantrowitz et al. SCHIZOPHRENIA RESEARCH
- Trospium Chloride Treatment of Overactive Bladder
- (2009) Kelly Biastre et al. ANNALS OF PHARMACOTHERAPY
- Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia
- (2009) Daniel J. Lodge et al. NEUROTOXICITY RESEARCH
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
- (2009) O. D. Howes et al. SCHIZOPHRENIA BULLETIN
- Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
- (2008) Anantha Shekhar et al. AMERICAN JOURNAL OF PSYCHIATRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started